Trial Profile
A retrospective study comparing Neuro-QoL patient reported outcomes over two years in new users of fingolimod and natalizumab with relapsing forms of multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 28 Apr 2017 Results (n=103) presented at the 69th Annual Meeting of the American Academy of Neurology
- 21 Nov 2016 New trial record